S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   443.05 (+0.92%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   443.05 (+0.92%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   443.05 (+0.92%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   443.05 (+0.92%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

$32.21
+1.83 (+6.02%)
(As of 11:32 AM ET)
Today's Range
$30.25
$32.38
50-Day Range
$21.79
$30.43
52-Week Range
$13.72
$32.38
Volume
253,611 shs
Average Volume
781,245 shs
Market Capitalization
$1.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Protagonist Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.5% Upside
$36.00 Price Target
Short Interest
Healthy
4.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Protagonist Therapeutics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$125,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.31) to ($1.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

Medical Sector

634th out of 957 stocks

Pharmaceutical Preparations Industry

299th out of 440 stocks

PTGX stock logo

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Stock Price History

PTGX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
PTGX Mar 2024 25.000 call
Protagonist Therapeutics Inc (PTGX)
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
111
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$38.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+18.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-127,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60 million
Book Value
$4.38 per share

Miscellaneous

Free Float
54,794,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
2.02
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 67)
    CEO, President, Secretary & Director
    Comp: $883.46k
  • Dr. Suneel K. Gupta Ph.D. (Age 65)
    Chief Development Officer
    Comp: $640.89k
  • Dr. Mark Smythe Ph.D. (Age 59)
    Founder & VP Technology
  • Mr. Asif Ali (Age 50)
    Executive VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh Ph.D.
    Executive VP & Chief Technical Officer
  • Mr. Matthew M. Gosling (Age 53)
    Executive VP & General Counsel
  • Ms. Carena Spivey
    Senior Vice President of Human Resources
  • Dr. Ashok Bhandari Ph.D. (Age 60)
    Executive VP & Chief Drug Discovery and Preclinical Development Officer
  • Dr. Scott Eric Plevy M.D.
    Executive VP & Therapeutic Head of Gastroenterology
  • Mr. Carter J. King (Age 53)
    Executive Vice President of Business Development














PTGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they anticipate the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2024?

Protagonist Therapeutics' stock was trading at $22.93 on January 1st, 2024. Since then, PTGX shares have increased by 32.5% and is now trading at $30.38.
View the best growth stocks for 2024 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its earnings results on Tuesday, February, 27th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.39. The firm had revenue of $60 million for the quarter, compared to analyst estimates of $60 million.

What ETF holds Protagonist Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.22%), Vanguard Group Inc. (5.47%), Point72 Asset Management L.P. (4.53%), Kynam Capital Management LP (3.48%), Price T Rowe Associates Inc. MD (1.43%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Suneel Gupta.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTGX) was last updated on 3/1/2024 by MarketBeat.com Staff

From Our Partners